BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI
admin By Colin Kellaher Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the…
Read Moreservice testing
Roche says Phase 3 studies for Alzheimer’s drug failed to meet primary endpoints
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of…
Read MoreGSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint
By Michael Susin GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients…
Read MoreAstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints
AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with…
Read MoreNovartis hemoglobinuria trial meets two primary endpoints
Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to…
Read MoreFresh data supports updated boosters targeting omicron subvariants, raising hopes more Americans will get the shot
A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support…
Read MoreFresh data supports updated boosters targeting omicron subvariants, raising hopes more Americans will get the shot
A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support…
Read MoreGSK respiratory syncytial virus vaccine Phase 3 trial meets primary endpoint
GSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine…
Read MoreEisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read More